U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Non-Recurrent Lung Carcinoma

MedGen UID:
1709031
•Concept ID:
C5237753
•
Neoplastic Process

Definition

A finding indicating that a patient with a history of lung carcinoma does not have evidence of recurrent disease. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVNon-Recurrent Lung Carcinoma

Recent clinical studies

Etiology

Clinical and economic impact of recurrence in early-stage non-small-cell lung cancer following complete resection.
West H, Hu X, Chirovsky D, Walker MS, Wang Y, Kaushiva A, Tepsick J, Samkari A
Future Oncol 2023 Jun;19(20):1415-1427. Epub 2023 May 23 doi: 10.2217/fon-2023-0024. PMID: 37218514
A prognostic risk model based on DNA methylation levels of genes and lncRNAs in lung squamous cell carcinoma.
Wang W, Xiang M, Liu H, Chu X, Sun Z, Feng L
PeerJ 2022;10:e13057. Epub 2022 Mar 24 doi: 10.7717/peerj.13057. PMID: 35356464Free PMC Article
Prognostic significance of a complement factor H autoantibody in early stage NSCLC.
Gottlin EB, Campa MJ, Gandhi R, Bushey RT, Herndon Nd JE, Patz EF Jr
Cancer Biomark 2022;34(3):385-392. doi: 10.3233/CBM-210355. PMID: 35068447
Eight-gene signature predicts recurrence in lung adenocarcinoma.
Zhang Y, Fan Q, Guo Y, Zhu K
Cancer Biomark 2020;28(4):447-457. doi: 10.3233/CBM-190329. PMID: 32508318
Differences in miRNA expression in early stage lung adenocarcinomas that did and did not relapse.
Edmonds MD, Eischen CM
PLoS One 2014;9(7):e101802. Epub 2014 Jul 16 doi: 10.1371/journal.pone.0101802. PMID: 25028925Free PMC Article

Diagnosis

Genetic and immunologic features of recurrent stage I lung adenocarcinoma.
Kratz JR, Li JZ, Tsui J, Lee JC, Ding VW, Rao AA, Mann MJ, Chan V, Combes AJ, Krummel MF, Jablons DM
Sci Rep 2021 Dec 8;11(1):23690. doi: 10.1038/s41598-021-02946-0. PMID: 34880292Free PMC Article
Sphingomyelin(d35:1) as a novel predictor for lung adenocarcinoma recurrence after a radical surgery: a case-control study.
Takanashi Y, Funai K, Sato S, Kawase A, Tao H, Takahashi Y, Sugimura H, Setou M, Kahyo T, Shiiya N
BMC Cancer 2020 Aug 24;20(1):800. doi: 10.1186/s12885-020-07306-1. PMID: 32831036Free PMC Article
Eight-gene signature predicts recurrence in lung adenocarcinoma.
Zhang Y, Fan Q, Guo Y, Zhu K
Cancer Biomark 2020;28(4):447-457. doi: 10.3233/CBM-190329. PMID: 32508318
Differences in miRNA expression in early stage lung adenocarcinomas that did and did not relapse.
Edmonds MD, Eischen CM
PLoS One 2014;9(7):e101802. Epub 2014 Jul 16 doi: 10.1371/journal.pone.0101802. PMID: 25028925Free PMC Article
Intensive care in patients with lung cancer: a multinational study.
Soares M, Toffart AC, Timsit JF, Burghi G, Irrazábal C, Pattison N, Tobar E, Almeida BFC, Silva UVA, Azevedo LCP, Rabbat A, Lamer C, Parrot A, Souza-Dantas VC, Wallet F, Blot F, Bourdin G, Piras C, Delemazure J, Durand M, Tejera D, Salluh JIF, Azoulay E; Lung Cancer in Critical Care (LUCCA) Study Investigators
Ann Oncol 2014 Sep;25(9):1829-1835. Epub 2014 Jun 20 doi: 10.1093/annonc/mdu234. PMID: 24950981

Therapy

Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer.
Zhang X, Wang X, Wen Y, Chen S, Zhou C, Wu F
Clin Transl Med 2024 Apr;14(4):e1649. doi: 10.1002/ctm2.1649. PMID: 38629624Free PMC Article
Decreased sphingomyelin (t34:1) is a candidate predictor for lung squamous cell carcinoma recurrence after radical surgery: a case-control study.
Takanashi Y, Funai K, Eto F, Mizuno K, Kawase A, Tao H, Kitamoto T, Takahashi Y, Sugimura H, Setou M, Kahyo T, Shiiya N
BMC Cancer 2021 Nov 17;21(1):1232. doi: 10.1186/s12885-021-08948-5. PMID: 34789180Free PMC Article
Sphingomyelin(d35:1) as a novel predictor for lung adenocarcinoma recurrence after a radical surgery: a case-control study.
Takanashi Y, Funai K, Sato S, Kawase A, Tao H, Takahashi Y, Sugimura H, Setou M, Kahyo T, Shiiya N
BMC Cancer 2020 Aug 24;20(1):800. doi: 10.1186/s12885-020-07306-1. PMID: 32831036Free PMC Article
Eight-gene signature predicts recurrence in lung adenocarcinoma.
Zhang Y, Fan Q, Guo Y, Zhu K
Cancer Biomark 2020;28(4):447-457. doi: 10.3233/CBM-190329. PMID: 32508318
Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages.
Sumiyoshi S, Yoshizawa A, Sonobe M, Kobayashi M, Fujimoto M, Tsuruyama T, Date H, Haga H
Lung Cancer 2013 Jul;81(1):53-9. Epub 2013 Apr 28 doi: 10.1016/j.lungcan.2013.04.003. PMID: 23632273

Prognosis

A prognostic risk model based on DNA methylation levels of genes and lncRNAs in lung squamous cell carcinoma.
Wang W, Xiang M, Liu H, Chu X, Sun Z, Feng L
PeerJ 2022;10:e13057. Epub 2022 Mar 24 doi: 10.7717/peerj.13057. PMID: 35356464Free PMC Article
Prognostic significance of a complement factor H autoantibody in early stage NSCLC.
Gottlin EB, Campa MJ, Gandhi R, Bushey RT, Herndon Nd JE, Patz EF Jr
Cancer Biomark 2022;34(3):385-392. doi: 10.3233/CBM-210355. PMID: 35068447
Genetic and immunologic features of recurrent stage I lung adenocarcinoma.
Kratz JR, Li JZ, Tsui J, Lee JC, Ding VW, Rao AA, Mann MJ, Chan V, Combes AJ, Krummel MF, Jablons DM
Sci Rep 2021 Dec 8;11(1):23690. doi: 10.1038/s41598-021-02946-0. PMID: 34880292Free PMC Article
Eight-gene signature predicts recurrence in lung adenocarcinoma.
Zhang Y, Fan Q, Guo Y, Zhu K
Cancer Biomark 2020;28(4):447-457. doi: 10.3233/CBM-190329. PMID: 32508318
Differences in miRNA expression in early stage lung adenocarcinomas that did and did not relapse.
Edmonds MD, Eischen CM
PLoS One 2014;9(7):e101802. Epub 2014 Jul 16 doi: 10.1371/journal.pone.0101802. PMID: 25028925Free PMC Article

Clinical prediction guides

A prognostic risk model based on DNA methylation levels of genes and lncRNAs in lung squamous cell carcinoma.
Wang W, Xiang M, Liu H, Chu X, Sun Z, Feng L
PeerJ 2022;10:e13057. Epub 2022 Mar 24 doi: 10.7717/peerj.13057. PMID: 35356464Free PMC Article
Prognostic significance of a complement factor H autoantibody in early stage NSCLC.
Gottlin EB, Campa MJ, Gandhi R, Bushey RT, Herndon Nd JE, Patz EF Jr
Cancer Biomark 2022;34(3):385-392. doi: 10.3233/CBM-210355. PMID: 35068447
Sphingomyelin(d35:1) as a novel predictor for lung adenocarcinoma recurrence after a radical surgery: a case-control study.
Takanashi Y, Funai K, Sato S, Kawase A, Tao H, Takahashi Y, Sugimura H, Setou M, Kahyo T, Shiiya N
BMC Cancer 2020 Aug 24;20(1):800. doi: 10.1186/s12885-020-07306-1. PMID: 32831036Free PMC Article
Eight-gene signature predicts recurrence in lung adenocarcinoma.
Zhang Y, Fan Q, Guo Y, Zhu K
Cancer Biomark 2020;28(4):447-457. doi: 10.3233/CBM-190329. PMID: 32508318
Intensive care in patients with lung cancer: a multinational study.
Soares M, Toffart AC, Timsit JF, Burghi G, Irrazábal C, Pattison N, Tobar E, Almeida BFC, Silva UVA, Azevedo LCP, Rabbat A, Lamer C, Parrot A, Souza-Dantas VC, Wallet F, Blot F, Bourdin G, Piras C, Delemazure J, Durand M, Tejera D, Salluh JIF, Azoulay E; Lung Cancer in Critical Care (LUCCA) Study Investigators
Ann Oncol 2014 Sep;25(9):1829-1835. Epub 2014 Jun 20 doi: 10.1093/annonc/mdu234. PMID: 24950981

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...